Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Candel Therapeutics (CADL) Accumulated Depreciation & Amortization (2020 - 2025)

Candel Therapeutics' Accumulated Depreciation & Amortization history spans 4 years, with the latest figure at $2.1 million for Q4 2023.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 161.12% to $2.1 million in Q4 2023 year-over-year; TTM through Dec 2023 was $2.1 million, a 161.12% increase, with the full-year FY2023 number at $2.1 million, up 161.12% from a year prior.
  • Accumulated Depreciation & Amortization hit $2.1 million in Q4 2023 for Candel Therapeutics, up from $1.8 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for CADL hit a ceiling of $2.1 million in Q4 2023 and a floor of $22000.0 in Q3 2021.
  • Historically, Accumulated Depreciation & Amortization has averaged $455066.7 across 4 years, with a median of $200000.0 in 2021.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: crashed 74.12% in 2021 and later skyrocketed 2627.27% in 2022.
  • Tracing CADL's Accumulated Depreciation & Amortization over 4 years: stood at $91000.0 in 2020, then soared by 119.78% to $200000.0 in 2021, then soared by 300.0% to $800000.0 in 2022, then skyrocketed by 161.12% to $2.1 million in 2023.
  • Business Quant data shows Accumulated Depreciation & Amortization for CADL at $2.1 million in Q4 2023, $1.8 million in Q3 2023, and $200000.0 in Q2 2023.